Skip to content

Secondary hypertension and modifiers

TL;DR — HHD severity is not explained by office BP alone. Primary aldosteronism (PA), CKD, obesity, sleep apnea, renal vascular disease, cortisol excess and coarctation can increase pressure burden or add pressure-independent remodeling. Compared with essential hypertension, PA is associated with higher odds of stroke, AF, HF and LVH, although comparison groups often differ in achieved pressure (Monticone 2018, PMID 29129575; Wu 2019, PMID 31261504). Obesity and CKD change geometry, fibrosis, biomarkers and treatment tolerance; OSA is associated with concentric remodeling, but CPAP cardiac effects are heterogeneous (Cuspidi 2020, PMID 31863113; Tadic 2022, PMID 35695237). Secondary-cause investigation should be trigger-based and documented before attributing disproportionate disease to “essential” hypertension.

1. Why modifiers matter

Two people with the same clinic BP may have different cardiac injury because of duration, nocturnal pressure, aldosterone, volume, obesity, renal function, arterial stiffness, ancestry, salt sensitivity and treatment adherence (Nadruz 2015, PMID 24804791; Mouton 2020, PMID 32163341).

Pattern Mechanistic concern Useful next evidence
Resistant hypertension PA, CKD, OSA, drugs, adherence, measurement error ABPM/home BP, medication reconciliation, targeted testing
Hypokalemia PA or diuretic effect Renin/aldosterone under interpretable conditions
Abrupt/severe onset Renovascular, endocrine or drug cause History, renal/endocrine evaluation
Disproportionate LVH/fibrosis PA, CKD, HCM, amyloid, coarctation CMR/echo pattern and cause-specific workup
Paroxysmal symptoms/labile BP Catecholamine excess Biochemical testing when pretest probability supports
Snoring/somnolence/nocturnal BP OSA Sleep assessment/testing
Arm–leg gradient or weak femoral pulses Coarctation Four-limb BP and aortic imaging
Cushingoid features Cortisol excess Guideline-directed endocrine testing

2. Primary aldosteronism: the clearest excess-risk phenotype

Across 31 observational studies, PA versus essential hypertension was associated with:

Outcome Odds ratio (95% CI)
Stroke 2.58 (1.93–3.45)
Atrial fibrillation 3.52 (2.06–5.99)
Heart failure 2.05 (1.11–3.78)
Left-ventricular hypertrophy 2.29 (1.65–3.17)

These estimates are from Monticone 2018 (PMID 29129575). A separate 31-study synthesis found PA groups had systolic BP 4.14 mm Hg higher (95% CI 2.60–5.68), so “BP-independent” excess should not be stated as fully pressure-matched (Wu 2019, PMID 31261504).

PA cardiac remodeling includes greater LV mass and diastolic/mechanical abnormalities; treatment can reverse part of the phenotype (Tsai 2021, PMID 33067554). The contemporary Endocrine Society guideline reflects expanding recognition and structured diagnosis/treatment, but its recommendations should not be collapsed into a single universal screening prevalence (Adler 2025, PMID 40658480).

3. Medical versus surgical PA

A retrospective cohort of medically treated PA found cardiometabolic outcomes and mortality depended on adequacy of mineralocorticoid-receptor blockade, using renin response as a treatment signal (Hundemer 2018, PMID 29129576). This raises a mechanistic distinction:

PA subtype/treatment Pressure pathway Remodeling question
Unilateral, adrenalectomy Removes autonomous source Completeness and tempo of LV/fibrosis regression
Bilateral, MRA Blocks receptor Dose limited by potassium/renal function
Inadequately blocked PA Persistent sodium/volume and receptor activity Residual cardiac risk despite clinic BP
Subclinical renin-independent aldosterone Continuous-risk construct Threshold for diagnosis and treatment

Population cohorts increasingly describe subclinical PA as a cardiovascular-risk continuum, but actionable thresholds and screening strategy remain unsettled (Hundemer 2024, PMID 38031887; Reincke 2021, PMID 34798068).

4. Chronic kidney disease

CKD contributes pressure, volume, anemia, uremic, inflammatory and mineral-bone signals. LVH and fibrosis can therefore reflect both HHD and CKD-associated cardiomyopathy (Kaesler 2023, PMID 38000021; Dobre 2024, PMID 38193308).

CKD feature Cardiac effect Diagnostic trap
Sodium/volume retention Higher preload and BP “Resistant” hypertension during overload
Nocturnal hypertension Persistent cardiac load Missed by office BP
Anemia High-output stress and hypertrophy Mass attributed only to pressure
Uremic/mineral signaling Fibrosis and microvascular disease Non-specific CMR markers
Dialysis shifts Load-dependent echo change Inconsistent timing of imaging
Hyperkalemia risk Limits RAAS/MRA therapy Undertreatment versus safety tradeoff

In CKD, out-of-office BP predicted prognosis better than routine measurement in earlier cohorts (Agarwal 2006, PMID 16609300). Reviews emphasize the joint prognostic effect of CKD, LVH and circadian BP abnormalities (Verdecchia 2022, PMID 35166125). LVH has also been associated with CKD progression, although directionality and confounding remain complex (Paoletti 2012, PMID 22460180).

5. Obesity

Obesity adds volume, sympathetic/RAAS activation, insulin resistance, inflammation, sleep apnea and altered natriuretic peptide biology. It interacts additively and sometimes synergistically with pressure (Woodiwiss 2015, PMID 25794954; Mouton 2020, PMID 32163341).

Obesity-related issue Consequence for HHD
BSA indexation Can conceal obesity-associated LVH
Increased plasma volume Larger chamber load
Epicardial/pericardial fat Restraint and inflammatory signaling
Lower natriuretic peptide HFpEF may be under-recognized
OSA overlap Nocturnal pressure and sympathetic activation
Deconditioning Symptoms less specific for cardiac limitation

In invasive phenotyping, obese HFpEF showed higher plasma volume, greater concentric remodeling, RV dysfunction and epicardial fat than nonobese HFpEF despite lower NT-proBNP (Obokata 2017, PMID 28381470).

6. Obstructive sleep apnea

OSA exposes the heart to intermittent hypoxemia, negative intrathoracic pressure, arousals, sympathetic surges and nocturnal BP. A meta-analysis specifically examined concentric LVH in OSA, supporting association but not proving that OSA is the sole cause (Cuspidi 2020, PMID 31863113).

CPAP meta-analysis found changes in cardiac mechanics across echocardiographic studies, but small samples, adherence and variable duration limit conclusions about hard HHD outcomes (Tadic 2022, PMID 35695237).

The useful causal sequence is therefore:

  1. Confirm OSA and nocturnal pressure rather than infer it from obesity.
  2. Treat OSA for established sleep/respiratory indications.
  3. Measure BP and remodeling responses separately.
  4. Do not promise LVH regression or event prevention from CPAP alone.

7. Renovascular disease and renal parenchymal disease

Secondary-hypertension reviews emphasize renal parenchymal disease, renovascular disease, PA, OSA and drug/substance causes as common actionable categories (Sarathy 2022, PMID 35227430).

Clue Raises suspicion for Boundary
Abrupt onset/worsening Renovascular disease Atherosclerosis is common without causal stenosis
Flash pulmonary edema Bilateral/severe renovascular physiology Other acute-HF causes remain possible
Creatinine rise with RAAS blockade Hemodynamically important renal artery disease Modest rise can occur without stenosis
Asymmetric kidneys/abdominal bruit Renovascular disease Imperfect sensitivity/specificity
Abnormal urinalysis/eGFR Parenchymal CKD May be consequence and cause

Testing should follow pretest probability because anatomical renal-artery narrowing does not automatically establish a causal or revascularization-responsive lesion.

8. Cortisol, catecholamine and thyroid excess

Prospective phenotyping of endogenous cortisol excess demonstrates cardiac structural/functional abnormalities beyond routine risk factors, while treatment response remains an active area (Morbach 2024, PMID 39556766). Earlier Cushing cohorts documented LV structural abnormalities and partial reversibility after cure (Toja 2012, PMID 21854405).

Pheochromocytoma can cause labile pressure, catecholamine toxicity and stress cardiomyopathy; the phenotype may be acute and reversible rather than classic chronic HHD (Agrawal 2017, PMID 28400922).

Thyroid status within the reference range has been associated with LV mass in hypertensive cohorts, but this does not justify attributing ordinary HHD to minor thyroid variation (Iida 2012, PMID 22664232).

9. Coarctation: repaired does not mean unloaded

Adults after coarctation repair may retain hypertension, abnormal wave reflection and LVH. Persistent hypertension and LVH remain clinically relevant even after anatomical repair (Egbe 2021, PMID 34247510).

Wave-reflection studies link late afterload to LVH, illustrating why brachial office BP may underestimate central load (Quail 2017, PMID 28115510).

10. Drugs and substances

Exposure class Pressure mechanism Documentation need
NSAIDs Sodium retention/renal effects Dose, duration, renal status
Stimulants/sympathomimetics Sympathetic activation Prescribed and nonprescribed use
Glucocorticoids Sodium/metabolic effects Cumulative exposure
Estrogen-containing agents Susceptible-person BP rise Temporal relation
Calcineurin inhibitors Renal/vascular effects Transplant context and levels
Licorice/mineralocorticoid mimics Apparent mineralocorticoid excess Dietary/supplement history
Alcohol Dose-related pressure and arrhythmia Quantified intake

Medication reconciliation and adherence assessment are part of secondary-cause work, not administrative preliminaries (Khatib 2014, PMID 24454721).

Open questions

  • What fraction of imaging-defined HHD is attributable to undiagnosed PA under contemporary screening strategies? (Monticone 2018, PMID 29129575; Adler 2025, PMID 40658480)
  • Which PA treatment target—BP, potassium, renin, aldosterone or imaging regression—best mediates event reduction? (Hundemer 2018, PMID 29129576; Tsai 2021, PMID 33067554)
  • Can nocturnal-BP and sleep-phenotype treatment prevent remodeling rather than only improve intermediate physiology? (Cuspidi 2020, PMID 31863113; Tadic 2022, PMID 35695237)
  • How should HHD thresholds and biomarkers be recalibrated in obesity and CKD? (Woodiwiss 2015, PMID 25794954; Dobre 2024, PMID 38193308)

References

  1. Monticone S, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41-50. PMID 29129575
  2. Wu X, et al. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15985. PMID 31261504
  3. Cuspidi C, et al. Targeting Concentric Left Ventricular Hypertrophy in Obstructive Sleep Apnea Syndrome. A Meta-analysis of Echocardiographic Studies. Am J Hypertens. 2020;33:310-315. PMID 31863113
  4. Tadic M, et al. The impact of continuous positive airway pressure on cardiac mechanics: Findings from a meta-analysis of echocardiographic studies. J Clin Hypertens (Greenwich). 2022;24:795-803. PMID 35695237
  5. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015;29:1-6. PMID 24804791
  6. Mouton AJ, et al. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020;126:789-806. PMID 32163341
  7. Tsai CH, et al. Left ventricular remodeling and dysfunction in primary aldosteronism. J Hum Hypertens. 2021;35:131-147. PMID 33067554
  8. Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453-2495. PMID 40658480
  9. Hundemer GL, et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51-59. PMID 29129576
  10. Hundemer GL, et al. Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation. 2024;149:124-134. PMID 38031887
  11. Reincke M, et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9:876-892. PMID 34798068
  12. Kaesler N, et al. Mapping cardiac remodeling in chronic kidney disease. Sci Adv. 2023;9:eadj4846. PMID 38000021
  13. Dobre MA, et al. Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives. Curr Opin Nephrol Hypertens. 2024;33:203-211. PMID 38193308
  14. Agarwal R. Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. Curr Opin Nephrol Hypertens. 2006;15:309-13. PMID 16609300
  15. Verdecchia P, et al. Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. Hypertension. 2022;79:1028-1036. PMID 35166125
  16. Paoletti E. Left ventricular hypertrophy and progression of chronic kidney disease. J Nephrol. 2012;25:847-50. PMID 22460180
  17. Woodiwiss AJ, et al. Obesity and left ventricular hypertrophy: the hypertension connection. Curr Hypertens Rep. 2015;17:539. PMID 25794954
  18. Obokata M, et al. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136:6-19. PMID 28381470
  19. Sarathy H, et al. Evaluation and Management of Secondary Hypertension. Med Clin North Am. 2022;106:269-283. PMID 35227430
  20. Morbach C, et al. Cardiovascular status in endogenous cortisol excess: the prospective CV-CORT-EX study. Eur J Endocrinol. 2024;191:604-613. PMID 39556766
  21. Toja PM, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf). 2012;76:332-8. PMID 21854405
  22. Agrawal S, et al. Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis. World J Cardiol. 2017;9:255-260. PMID 28400922
  23. Iida M, et al. Thyroid hormone within the normal range is associated with left ventricular mass in patients with hypertension. J Am Soc Hypertens. 2012;6:261-9. PMID 22664232
  24. Egbe AC, et al. Persistent Hypertension and Left Ventricular Hypertrophy After Repair of Native Coarctation of Aorta in Adults. Hypertension. 2021;78:672-680. PMID 34247510
  25. Quail MA, et al. Abnormal Wave Reflections and Left Ventricular Hypertrophy Late After Coarctation of the Aorta Repair. Hypertension. 2017;69:501-509. PMID 28115510
  26. Khatib R, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One. 2014;9:e84238. PMID 24454721